Optic Neuropathy Market Share, Treatment, Causes, Pipeline Review, H2 2016
Global Markets Direct's, 'Optic Neuropathy - Pipeline Review, H2 2016', provides an overview of the Optic Neuropathy pipeline landscape.
Global Markets Direct's, 'Optic Neuropathy - Pipeline Review, H2 2016', provides an overview of the Optic Neuropathy pipeline landscape.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Optic</strong> <strong>Neuropathy</strong> <strong>Market</strong> <strong>Share</strong>, Size, <strong>Treatment</strong>, <strong>Causes</strong>,<br />
<strong>Pipeline</strong> <strong>Review</strong>, <strong>H2</strong> <strong>2016</strong><br />
Summary<br />
Global <strong>Market</strong>s Direct's, '<strong>Optic</strong> <strong>Neuropathy</strong> - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H2</strong> <strong>2016</strong>', provides an overview of the <strong>Optic</strong><br />
<strong>Neuropathy</strong> pipeline landscape.<br />
The report provides comprehensive information on the therapeutics under development for <strong>Optic</strong> <strong>Neuropathy</strong>,<br />
complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration<br />
(RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its<br />
complete research and development history and latest news and press releases. Additionally, the report provides<br />
an overview of key players involved in therapeutic development for <strong>Optic</strong> <strong>Neuropathy</strong> and features dormant and<br />
discontinued projects.<br />
Access Full Report with TOC @ http://www.radiantinsights.com/research/optic-neuropathy-pipeline-review-h2-<br />
<strong>2016</strong><br />
Global <strong>Market</strong>s Direct's report features investigational drugs from across globe covering over 20 therapy areas and<br />
nearly 3,000 indications. The report is built using data and information sourced from Global <strong>Market</strong>s Direct's<br />
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor<br />
presentations and featured press releases from company/university sites and industry-specific third party sources.<br />
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that<br />
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes<br />
ensure that the most recent developments are captured on a real time basis.<br />
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision<br />
making capabilities and helps to create effective counter strategies to gain competitive advantage.<br />
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.<br />
Scope<br />
- The report provides a snapshot of the global therapeutic landscape of <strong>Optic</strong> <strong>Neuropathy</strong><br />
- The report reviews pipeline therapeutics for <strong>Optic</strong> <strong>Neuropathy</strong> by companies and universities/research institutes<br />
based on information derived from company and industry-specific sources<br />
- The report covers pipeline products based on various stages of development ranging from pre-registration till<br />
discovery and undisclosed stages<br />
- The report features descriptive drug profiles for the pipeline products which includes, product description,<br />
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved <strong>Optic</strong> <strong>Neuropathy</strong> therapeutics and enlists all their major and minor<br />
projects<br />
- The report assesses <strong>Optic</strong> <strong>Neuropathy</strong> therapeutics based on drug target, mechanism of action (MoA), route of<br />
administration (RoA) and molecule type<br />
- The report summarizes all the dormant and discontinued pipeline projects<br />
- The report reviews latest news related to pipeline therapeutics for <strong>Optic</strong> <strong>Neuropathy</strong><br />
Reasons To Buy<br />
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies<br />
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain<br />
competitive advantage<br />
- Identify and understand important and diverse types of therapeutics under development for <strong>Optic</strong> <strong>Neuropathy</strong><br />
- Identify potential new clients or partners in the target demographic<br />
- Develop strategic initiatives by understanding the focus areas of leading companies<br />
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics<br />
- Devise corrective measures for pipeline projects by understanding <strong>Optic</strong> <strong>Neuropathy</strong> pipeline depth and focus of<br />
Indication therapeutics<br />
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most<br />
attractive projects to enhance and expand business potential and scope<br />
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove<br />
them from pipeline<br />
Buy a Sample copy of This Report @ http://www.radiantinsights.com/research/optic-neuropathy-pipelinereview-h2-<strong>2016</strong>/request-sample<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 5<br />
List of Figures 5<br />
Introduction 6<br />
Global <strong>Market</strong>s Direct Report Coverage 6<br />
<strong>Optic</strong> <strong>Neuropathy</strong> Overview 7<br />
Therapeutics Development 8<br />
<strong>Pipeline</strong> Products for <strong>Optic</strong> <strong>Neuropathy</strong> - Overview 8<br />
<strong>Pipeline</strong> Products for <strong>Optic</strong> <strong>Neuropathy</strong> - Comparative Analysis 9<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Therapeutics under Development by Companies 10<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Therapeutics under Investigation by Universities/Institutes 11<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - <strong>Pipeline</strong> Products Glance 12<br />
Late Stage Products 12<br />
Clinical Stage Products 13<br />
Early Stage Products 14<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Products under Development by Companies 15<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Products under Investigation by Universities/Institutes 16<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Companies Involved in Therapeutics Development 17<br />
Amgen Inc. 17<br />
BioAxone BioSciences, Inc. 18<br />
Inotek Pharmaceuticals Corporation 19<br />
Ironwood Pharmaceuticals, Inc. 20<br />
PharmatrophiX, Inc. 21<br />
Quark Pharmaceuticals, Inc. 22<br />
Regenera Pharma Ltd. 23<br />
<strong>Optic</strong> <strong>Neuropathy</strong> - Therapeutics Assessment 24<br />
Assessment by Monotherapy Products 24
Assessment by Target 25<br />
Assessment by Mechanism of Action 27<br />
Assessment by Route of Administration 29<br />
Access Full Report with TOC @ http://www.radiantinsights.com/research/optic-neuropathy-pipeline-review-h2-<br />
<strong>2016</strong><br />
About Us:<br />
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence<br />
requirements. We assist and facilitate organizations and individuals procure market research reports, helping them<br />
in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries<br />
and a host of micro markets. In addition to over extensive database of reports, our experienced research<br />
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research<br />
solutions.<br />
Contact Details:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
Radiant Insights, Inc<br />
28 2nd Street,<br />
Suite 3036 San Francisco,<br />
CA 94105 United States<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Website: http://www.radiantinsights.com/<br />
Email: sales@radiantinsights.com<br />
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com
Change language